Jon Mcclelland Lockard

Array ( [id] => 20302450 [patent_doc_number] => 12448428 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => HLA class II-restricted t cell receptors against RAS with G12R mutation [patent_app_type] => utility [patent_app_number] => 17/424591 [patent_app_country] => US [patent_app_date] => 2020-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 15180 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17424591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533637 [patent_doc_number] => 20220112246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => CONFORMATIONAL EPITOPE OF HEPATITIS B SURFACE ANTIGEN AND ANTIBODY BINDING SPECIFICALLY THERETO [patent_app_type] => utility [patent_app_number] => 17/417603 [patent_app_country] => US [patent_app_date] => 2020-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175565 [patent_doc_number] => 20200222533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => Methods Of Treatment Of Keloid Using An Anti-VEGF Agent [patent_app_type] => utility [patent_app_number] => 16/740143 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8648 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15831929 [patent_doc_number] => 20200131246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION [patent_app_type] => utility [patent_app_number] => 16/739559 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4798 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16739559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443821 [patent_doc_number] => 20220064326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => HIGHLY MODULAR BIEPITOPIC AND BISPECIFIC CAR-T CELLS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/420251 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16296299 [patent_doc_number] => 20200282022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES [patent_app_type] => utility [patent_app_number] => 16/720970 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16720970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16466780 [patent_doc_number] => 20200368317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => METHODS AND COMPOSITIONS OF NEUREGULINS FOR PREVENTING, TREATING OR DELAYING PRESERVED EJECTION FRACTION CARDIAC FAILURE [patent_app_type] => utility [patent_app_number] => 16/714397 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16714397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19763205 [patent_doc_number] => 12221479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-11 [patent_title] => Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies [patent_app_type] => utility [patent_app_number] => 17/416958 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12009 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15863131 [patent_doc_number] => 20200138969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => DLL3 MODULATORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/706174 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16706174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345285 [patent_doc_number] => 20240254248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => CD40 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/298414 [patent_app_country] => US [patent_app_date] => 2019-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828615 [patent_doc_number] => 20200129589 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => PREDICTIVE AND PROGNOSTIC BIOMARKERS RELATED TO ANTI-ANGIOGENIC THERAPY OF METASTATIC COLORECTAL CANCER [patent_app_type] => utility [patent_app_number] => 16/690459 [patent_app_country] => US [patent_app_date] => 2019-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16690459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336080 [patent_doc_number] => 20220002411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => METHODS FOR TREATING IMMUNE RELATED OCULAR DISORDERS [patent_app_type] => utility [patent_app_number] => 17/292997 [patent_app_country] => US [patent_app_date] => 2019-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129205 [patent_doc_number] => 12371507 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => CDCP1 antibodies and antibody drug conjugates [patent_app_type] => utility [patent_app_number] => 17/292257 [patent_app_country] => US [patent_app_date] => 2019-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 54 [patent_no_of_words] => 44479 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15831913 [patent_doc_number] => 20200131238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => METHOD FOR PROMOTING ADIPOCYTE DIFFERENTIATION AND OBESITY-RELATED DISEASE TREATMENT [patent_app_type] => utility [patent_app_number] => 16/662457 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16662457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17221821 [patent_doc_number] => 11174312 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-16 [patent_title] => Nav1.9 target polypeptide, antibody and antibody fragment combined with same, and related pharmaceutical composition [patent_app_type] => utility [patent_app_number] => 16/657471 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 5122 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17134836 [patent_doc_number] => 11136382 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Antibodies and antibody fragments for binding to NAV1.9 polypeptides and methods for using same to treat pain-related disease [patent_app_type] => utility [patent_app_number] => 16/657515 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 4896 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435417 [patent_doc_number] => 20200031892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => COMPOSITION COMPRISING NEUREGULIN FOR ORGAN PERFUSION, PRESERVATION OR REPERFUSION, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/586589 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363615 [patent_doc_number] => 20200017572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION [patent_app_type] => utility [patent_app_number] => 16/582486 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16582486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16222762 [patent_doc_number] => 20200247878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same [patent_app_type] => utility [patent_app_number] => 16/573966 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16320174 [patent_doc_number] => 10780121 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => FLT3L-based chimeric proteins [patent_app_type] => utility [patent_app_number] => 16/570553 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 37 [patent_no_of_words] => 29114 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570553 [rel_patent_id] =>[rel_patent_doc_number] =>)